273 related articles for article (PubMed ID: 34009333)
1. Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case.
Montnach J; Baró I; Charpentier F; De Waard M; Loussouarn G
Europace; 2021 Jul; 23(7):1124-1133. PubMed ID: 34009333
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
[TBL] [Abstract][Full Text] [Related]
3. The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.
Bakhshaliyev N; Özdemir R
Ann Noninvasive Electrocardiol; 2021 Jul; 26(4):e12846. PubMed ID: 33956361
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.
Özdemir İH; Özlek B; Özen MB; Gündüz R; Çetin N; Bilge AR
Int J Clin Pract; 2021 Feb; 75(2):e13896. PubMed ID: 33280207
[TBL] [Abstract][Full Text] [Related]
5. System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.
Khan AA; Khan Z
Chem Biol Interact; 2020 Dec; 332():109299. PubMed ID: 33098839
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients.
Million M; Lagier JC; Hourdain J; Franceschi F; Deharo JC; Parola P; Brouqui P
Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241095
[No Abstract] [Full Text] [Related]
7. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients.
Bakhshaliyev N; Uluganyan M; Enhos A; Karacop E; Ozdemir R
J Electrocardiol; 2020; 62():59-64. PubMed ID: 32827987
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
[TBL] [Abstract][Full Text] [Related]
9. In vitro safety "clinical trial" of the cardiac liability of drug polytherapy.
Charrez B; Charwat V; Siemons B; Finsberg H; Miller EW; Edwards AG; Healy KE
Clin Transl Sci; 2021 May; 14(3):1155-1165. PubMed ID: 33786981
[TBL] [Abstract][Full Text] [Related]
10. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
11. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
Gunay S; Caliskan S; Sigirli D; Sahin E
Bratisl Lek Listy; 2020; 121(11):817-821. PubMed ID: 33164544
[TBL] [Abstract][Full Text] [Related]
12. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
[TBL] [Abstract][Full Text] [Related]
13. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
[TBL] [Abstract][Full Text] [Related]
14. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
Cipriani A; Zorzi A; Ceccato D; Capone F; Parolin M; Donato F; Fioretto P; Pesavento R; Previato L; Maffei P; Saller A; Avogaro A; Sarais C; Gregori D; Iliceto S; Vettor R
Int J Cardiol; 2020 Oct; 316():280-284. PubMed ID: 32439366
[TBL] [Abstract][Full Text] [Related]
15. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
Bun SS; Taghji P; Courjon J; Squara F; Scarlatti D; Theodore G; Baudouy D; Sartre B; Labbaoui M; Dellamonica J; Doyen D; Marquette CH; Levraut J; Esnault V; Bun SS; Ferrari E
Clin Pharmacol Ther; 2020 Nov; 108(5):1090-1097. PubMed ID: 32588427
[TBL] [Abstract][Full Text] [Related]
16. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Zequn Z; Yujia W; Dingding Q; Jiangfang L
Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
[TBL] [Abstract][Full Text] [Related]
17. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
Shah RR
J Clin Pharm Ther; 2021 Feb; 46(1):17-27. PubMed ID: 32981089
[TBL] [Abstract][Full Text] [Related]
18. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
[TBL] [Abstract][Full Text] [Related]
19. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
[TBL] [Abstract][Full Text] [Related]
20. Prolonged QT Interval in a Patient With Coronavirus Disease-2019: Beyond Hydroxychloroquine and Azithromycin.
Anupama BK; Adhikari S; Chaudhuri D
J Investig Med High Impact Case Rep; 2020; 8():2324709620948407. PubMed ID: 32762368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
